Facebook
X
LinkedIn
ForwardAn Expanding Toolbox: A Glimpse into Novel and Emerging Systemic Therapies for Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer
Program Description
The management of hormone receptor–positive (HR+), HER2–negative (HER2-) metastatic breast cancer (mBC) is evolving rapidly. CDK4/6 inhibitors (CDK4/6i) with endocrine therapy (ET) remain a standard first-line option, but growing adjuvant use means many patients now present with prior CDK4/6i exposure or ET resistance. This earlier resistance is reshaping molecular testing and treatment sequencing. At the same time, new biomarker-driven strategies are expanding opportunities for patients with targetable mutations (e.g., PIK3CA, AKT1) or ET resistance (e.g., ESR1). These agents show meaningful activity, though questions remain around optimal sequencing, patient selection, and clinical integration.
To explore the implications of these advances, this activity synthesizes insights from a survey of five BC specialists alongside discussion of consensus-based guidelines, pivotal phase 3 trial data, and ongoing research efforts. By integrating real-world practice patterns with the latest evidence, the program aims to equip oncology clinicians with practical strategies for optimizing care for their own patients with HR+/HER2– mBC.
Target Audience
This activity is intended for medical oncologists, medical oncology fellows, oncology nurse practitioners (NPs) and physician associates (PAs), oncology nurses, oncology pharmacists, and other healthcare professionals involved in the management of patients with BC.
Learning Objectives
Upon completion of this activity, the learner should be able to:
- Identify the role of actionable biomarker mutations (e.g. ESR1, PIK3A, AKT1) in the selection of therapy for patients with HR+/HER2- mBC to improve individualized treatment selection
- Apply evidence-based strategies for managing and monitoring adverse effects (AEs) associated with novel ETs alone and in combination with other targeted therapies in HR+/HER2- mBC to improve patient tolerability, treatment adherence, and persistence
- Appraise clinical efficacy and safety data surrounding approved and emerging ETs alone and in combination with other targeted therapies in HR+/HER2- mBC, including their impact on patients with prior treatment resistance, to improve decision-making across practice settings
Erica L. Mayer, MD, MPH
Kom. l Jhaveri, MD, FACPOther Surveyed Experts
Adam Brufsky, MD, PhD
Professor of Medicine
Co-Director, Cancer Therapeutics Program
UPMC Hillman Cancer Center, University of Pittsburgh
Pittsburgh, PA
Sarah Sammons, MD
Associate Director, Metastatic Breast Cancer Program
Susan F. Smith Center for Women’s Cancers
Assistant Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Virginia Kaklamani, MD, DSc
Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
A.B. Alexander Distinguished Chair in Oncology
Leader, Breast Oncology Program
UT Health San Antonio, MD Anderson Cancer Center
Jointly provided by Partners for Advancing Clinical Education and EfficientCME
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Efficient LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Designation Statement
(Universal Activity Number - XXXXXX)
Type of Activity: Knowledge-based
For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
PA Continuing Medical Education
Faculty and Disclosure of Conflicts of Interest
Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.
Dr. Erica Mayer, moderator for this educational activity, has the following relevant financial relationships:
- Consultant, advisor, or speaker for AstraZeneca, Genentech, Lilly, and Novartis
Dr. Komal Jhaveri, presenter for this educational activity, has the following relevant financial relationships:
- Consultant, advisor, or speaker for AbbVie, AstraZeneca, Blueprint Medicine, Bristol Myers Squibb, Daiichi Sankyo, Eisai, Genentech, and Gilead Sciences
- Consultant/advisory board role: Novartis, Pfizer, Genentech, Eisai, AstraZeneca, Blueprint Medicines, Daiichi Sankyo, Menarini/Stemline, Gilead, Scorpion Therapeutics, Bicycle Therapeutics, Olema Pharmaceuticals, Lilly/Loxo Oncology, Merck Pharmaceuticals, Zymeworks, Halda Therapeutics, Arivinas and Rayzebio
- Research Funding support to the Institution: Novartis, Genentech, AstraZeneca, Pfizer, Lilly/Loxo Oncology, Zymeworks, Gilead, PUMA Biotechnology, Merck Pharmaceuticals, Scorpion Therapeutics, Rayzebio, Eisai and Blueprint Medicines.
Dr. Adam M. Brufsky, planner for this educational activity, has the following relevant financial relationships:
- Consultant, advisor, or speaker for Agendia, AstraZeneca, Daiichi, Gilead, Lilly, Myriad, Pfizer and Roche.
Dr. Sarah Sammons, planner for this educational activity, has the following relevant financial relationships:
- Consultant, advisor, or speaker for AstraZeneca, Daiichi, Gilead, Incyclix, Lilly, Novartis, Pfizer/Seattle Genetics, Sankyo, and Sermonix.
- Researcher for Daiichi Sankyo, Relay Therapeutics, SEAGEN, and Sermonix.
Dr. Virginia Kaklamani, planner for this educational activity, has the following relevant financial relationships:
- Consultant, advisor, or speaker for AstraZeneca, Genentech, Gilead, Lilly, Novartis, and Pfizer.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Commercial Support
This activity is supported by independent educational grants from Genentech and Lilly.
Available Credit
- 0.75 AAPA Category I CME
- 0.75 ACPE Pharmacy
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC
- 0.75 Attendance